Search
Sacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalIt was approved by the FDA after being given the status of priority review for on July 7, 2015. … Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection
Polihexanide
go.drugbank.com/drugs/DB12277ApprovedInvestigational[A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]
Clodronic acid
go.drugbank.com/drugs/DB00720ApprovedInvestigationalVet approved[A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. … [A1923] clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]
Trofinetide
go.drugbank.com/drugs/DB06045Approved, making trofinetide the first and only treatment approved for Rett syndrome in the European Union. … [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union.
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.
Products: ZYEX-T, HEAMIC-T (Tranexamic Acid Injection 100mg/mL)Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalThe effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. … Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256
Mixtures: SITAGLIPTIN E METFORMINA GALENICUM, SITAGLIPTIN E METFORMINA GALENICUMQuinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Newer dopamine receptor agonists such as quinagolide and [DB00248] are shown to effectively inhibit prolactin secretion with improved efficacy over [DB01200].
Categories: Dopamine D2 Receptor AgonistsAminobenzoic acid
go.drugbank.com/drugs/DB02362ApprovedWithdrawnA member of the vitamin B complex. It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.
Labetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigationalLabetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. … [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Categories: Adrenergic alpha-1 Receptor AntagonistsProducts: JOYALE-TTeniposide
go.drugbank.com/drugs/DB00444ApprovedInvestigationalAccumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.